RedHill Biopharma RDHL Estimates

NASDAQ RDHL
$0.69 +0.03 (+4.88%)
As of: Sep 9, 2026 · 12:47 PM EDT
Analyst Estimates

RedHill Biopharma Ltd. Revenue Estimates

Periods 26
Next Period Q2 23
Consensus 24.80 M

Analysts expect RedHill Biopharma Ltd. to report revenue of 24.80 M for Q2 23, against a range of 23.56 M to 26.05 M. The most recent reported quarter, Q1 23, came in at 3.60 M, a 85.0% miss against the 24.07 M consensus.

Metric Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27
Reported (Actual) 21.60 M22.10 M18.24 M18.35 M17.55 M12.80 M3.60 M--------
High Estimate 24.73 M26.43 M25.83 M21.37 M18.53 M18.19 M26.25 M26.05 M12.91 M7.11 M3.65 M22.82 M17.58 M9.89 M1.88 M
Low Estimate 21.31 M24.30 M23.52 M20.08 M16.80 M15.99 M21.90 M23.56 M11.79 M6.62 M3.27 M21.37 M14.61 M8.60 M1.74 M
Consensus Estimate 23.02 M25.37 M24.68 M20.73 M17.66 M17.09 M24.07 M24.80 M12.35 M6.87 M3.46 M22.10 M16.09 M9.25 M1.81 M
Analyst Estimates

RedHill Biopharma Ltd. Earnings Per Share (EPS) Estimates

Periods 26
Next Period Q4 22
Consensus 0.00

Analysts expect RedHill Biopharma Ltd. to report earnings per share of 0.00 for Q4 22, against a range of 0.00 to 0.00. The most recent reported quarter, Q1 23, came in at -1.25.

Metric Q3 21Q4 21Q1 22Q2 22Q3 22Q4 22Q1 23Q2 23Q3 23Q4 23Q1 24Q2 24Q3 24Q4 24Q1 25Q2 25Q3 25Q4 25Q1 26Q2 26Q3 26Q4 26Q1 27Q2 27Q3 27Q4 27
Reported (Actual) -500.00-500.00-30.00-20.00-60.00--1.25-------
High Estimate -426.33-435.81-281.87-19.25-10.100.00--7.1442.95145.767.66-84.50-20.39112.49
Low Estimate -473.95-475.49-340.83-22.91-11.040.00--8.4636.41126.966.82-91.80-21.67102.21
Consensus Estimate -450.14-455.65-311.35-21.08-10.570.00--7.8039.68136.367.24-88.15-21.03107.35